Glucagon-Like Peptide-1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.
GLP-1 receptor agonists just scored another win for peptide research. In a massive German study, researchers tracked over 45,000 people with both type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD)—that’s fatty liver disease with metabolic complications. The question: How do GLP-1 RAs stack up against SGLT-2 inhibitors when it comes to protecting the liver, not just the heart?
Diabetes Obes Metab
by Maier GA, Hofmann RA, Roden M et al.
“Glucagon-Like Peptide-1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Maier GA(1), Hofmann RA(1), Roden M(2)(3)(4), Rathmann W(1), Kuss O(1)(2)(5). Author information: (1)Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. (2)German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany. (3)Division of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich Heine University, University Hospital, Düsseldorf, Germany. (4)Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. (5)Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany. AIMS: Treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. While glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver-related outcomes remains unclear. This study compared the effectiveness of GLP-1 RAs versus SGLT-2 inhibitors on major adverse liver outcomes (MALO), liver cirrhosis and all-cause mortality in people with MASLD and type 2 diabetes. MATERIALS AND METHODS: This active comparator, new-user cohort study used claims data from Germany (2005-2024), including 45 256 people with MASLD and type 2 diabetes. New users of GLP-1 RAs (n = 9993) and SGLT-2 inhibitors (n = 35 263) were weighted using matching weights. The primary outcome was MALO, while secondary outcomes comprised individual MALO components (decompensation events, liver transplantation, hepatocellular carcinoma (HCC)), liver cirrhosis and all-cause mortality. Hazard ratios (HR) with 95% confidence intervals (CI) were estimated with weighted Cox proportional hazard models. RESULTS: Over a median 4.3-year follow-up, new users of GLP-1 RAs had a lower hazard of MALO (HR 0.91, 95% CI 0.78-1.07). This association appeared stronger using an on-treatment approach (HR 0.78, 95% CI 0.58-1.03) and when restricting to hospital diagnoses in primary position (HR 0.77, 95% CI 0.56-1.07). Benefits were also observed for liver cirrhosis (HR 0.88), decompensation events (HR 0.91), HCC (HR 0.76), but not all-cause mortality (HR 1.04). CONCLUSIONS: GLP-1 RAs were associated with a potentially lower hazard for incident MALO and liver cirrhosis compared with SGLT-2 inhibitors in people with MASLD and type 2 diabetes, suggesting a possible therapeutic advantage for liver-specific outcomes in this population. © 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.”
The data set here is no joke: nearly 10,000 new GLP-1 RA users, more than 35,000 on SGLT-2 inhibitors, and over four years of follow-up. Researchers wanted to see who developed major adverse liver outcomes (MALO), cirrhosis, liver cancer, or needed a transplant.
Key takeaway: The GLP-1 RA group had a lower hazard for major liver issues. The effect was even stronger when looking at those who stuck with treatment or only counting hospital diagnoses. Here’s the breakdown:
9% lower hazard for MALO (HR 0.91)
12% lower hazard for cirrhosis (HR 0.88)
24% lower hazard for liver cancer (HCC) (HR 0.76)
No increase or decrease for all-cause mortality (HR 1.04)
It’s not a miracle, but it’s clear GLP-1 receptor agonists did better for liver endpoints than SGLT-2 inhibitors in this high-risk group. The effect sizes tightened up for those who were compliant with their peptide regimen.
For anyone following the peptide world, this is validation. Liver outcomes matter, and GLP-1 agonists are now standing out beyond just blood sugar or weight control. The details are deep, but the direction is promising. Expect more eyes on peptides in metabolic and liver research. For more studies and updates, hit the peptide research index.
The future of peptide-driven liver support is just getting started.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.